Meet our team
Predictive Oncology
Corporate Leadership
Raymond F. Vennare
Chief Executive Officer
and Chairman of the Board
Raymond F. Vennare became Predictive Oncology’s CEO and Chairman of the Board on November 1, 2022. He has served on the Board of Directors since September of 2021.
Josh Blacher, MBA
Interim Chief Financial Officer
Josh Blacher, MBA is the Interim Chief Financial Officer for Predictive Oncology. As a strategic and operational CFO with more than 20 years of experience in leadership for private and Nasdaq-listed companies, Mr. Blacher specializes in the life science and biotech sectors.
Arlette H. Uihlein, MD
SVP, Translational Medicine and Drug Discovery, Medical Director
Arlette H. Uihlein, MD, FCAP, FASCP, is Senior Vice President of Translational Medicine and Drug Discovery for Predictive Oncology and Site Leader of Helomics. She has also served as Medical Director of Helomics® Clinical and Research Labs since 2011.
Larry DeLucas, Ph.D.
SVP, Biologics
Dr. DeLucas is the Senior Vice President of Biologics for Predictive Oncology. He oversees Predictive Oncology’s solubility and stability contracts for numerous pharmaceutical/biotech companies.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.
News & resources
“The way in which Predictive Oncology utilizes the power of predictive models offers the potential to optimize the utilization of resources, improve patient outcomes, and...
Life Sciences Knowledge Hub, recognized as the fastest-growing life sciences media platform, met with our Chief Executive Officer, Raymond F. Vennare, and Chief Business...
Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment...